Skip to main content Skip to main menu
University of Florida Health University of Florida
Cancer Center
Contact Us: (352) 273-8010
Research Overview

National Cancer Institute

TitleKeywordsActivity CodeFOALOI Due DateApplication Due Date
Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01 Clinical Trial Optional)Phenotype, biomarkers, premastatic R01PAR-22-1312/5/2025
NCI Mentored Research Scientist Development Award to Promote Diversity (K01 Independent Clinical Trial Not Allowed)Diversity, Research Scientist Development, Clinical TrialK01PAR-21-2952/12/2025
National Cancer Institute's Investigator - Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)clinical trials, early phase, treatment, diagnosis, innovative therapiesR01PAR-24-0851/5/20242/5/2025
NCI Mentored Research Scientist Development Award to Promote Diversity (K08 No Independent Clinical Trials)early-career, mentored, diversity, K08PAR-21-3002/12/2025
(NOSI): Technologies and Informatics Tools for Cancer MetabolomicsInformatics, Metabolomics, Molecular Analysis, lipidomics, low-resourceR33,R61,R21,U24,U01NOT-CA-22-08312/30/2024
(NOSI): Basic Mechanisms of Cannabis and Cannabinoid Action in CancerCannabis, cannabinoids, interception, therapeutic applications, biologyK22,R01,K08,K01,R21,R03,K99/R00NOT-CA-22-0857/4/2027
(NOSI): Utilization of Cohorts and Prospective Study Designs for Liquid Biopsy Assay Validation for Early Detection of CancersEarly detection, Advanced biomarkers, High-risk individuals, early detectionR43/R44,R21,R01,UH2/UH3,R41/R42,U01NOT-CA-23-0047/1/2025
(NOSI): Adaptive Biomaterials for Cancer BiologyAdaptive biomaterials, Biology, biomaterials, diagnostic, therapeuticR01,K22,K99/R00NOT-CA-23-0305/6/2025
(NOSI): Technology Development for Cancer Control and Population Science ResearchMicrobiome, development, progression, therapeutic targetsU01,R21,R61,R33,U24NOT-CA-23-03712/30/2024
(NOSI): RNA Modifications in Cancer BiologyPrecision prevention, AI, high risk, prevention strategiesR33,R21,U01,R61,R03NOT-CA-23-0601/7/2026
(NOSI): Research on HIV - associated MalignanciesSocial, behavioral , communication, education, strategies, prevention, early detection, treatment, health disparities R21,R01NOT-CA-23-0709/7/2026
(NOSI): Administrative Supplements for Enhancing Recruitment and Retention of Diverse Populations to Cancer Screening, Cancer Prevention and Symptom Management Clinical TrialsInnovative technologies, prevention, early detection, new technologies, Admin SuppNOT-CA-23-0716/30/2025
(NOSI): Pragmatic Trials in Low Resource Settingsclinical trials, Low-resource settings, interventions, routine healthcare, underserved populations, health disparitiesUG3/UH3NOT-CA-23-07811/17/2025
(NOSI): Research Projects to Develop Oncoaging Models for Cancer ResearchEquity, equitable care, interventionsR21,R01NOT-CA-23-0927/30/2027
(NOSI): National Cancer Institute Entrepreneurial Education Programs to Facilitate Commercialization of Cancer Relevant TechnologiesSocial determinants, health disparities, SDOH, evaluating interventionsR25NOT-CA-24-0011/7/2027
(NOSI): Exploratory Cancer Immunology Projects and Technologies (ExCITe)Clinical decision support tools, CDSTs, care delivery, clinical decision-making, patient outcomesR21NOT-CA-24-01611/16/2026
(NOSI): National Cancer Institute Supports Applications for the Mentored Research Scientist Development Awards (K01) Within the Mission of the Division of Cancer Control and Population SciencesMentored Research, Development Awards, Population Sciences, susceptibility factors, genetic, epigenetic, immunological, inflammatory, hormonal, social, cultural, ethnic, Intervention development, obacco, alcohol, diet, physical activity, behavioral, psychosocialK01NOT-CA-24-0225/7/2029
(NOSI): National Cancer Institute Supports Applications for the Mentored Research Scientist Development Awards (K01) Within the Mission of the Division of Cancer PreventionMentored Research, Development Awards, Down syndromeK01NOT-CA-24-0235/7/2029
(NOSI): Epidemiologic Studies to Assess the Impact of Incretin Mimetics on New and Recurrent Cancer Riskdisparities, epidemiology, R00, R01, R21, K08, K22, K99, NOT-CA-24-0375/9/2026
The NCI Worta McCaskill - Stevens Career Development Award for Community Oncology and Prevention Research (K12 Clinical Trial Optional)Community oncology, Cancer prevention research, Career development, Clinical trials, early career K12PAR-24-1536/18/2025
NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional)pilot, small projects, short termR03PAR-23-0582/24/2025
(NOSI): Advancing Diet and Physical Activity Biomarkers for Assessing Lifestyle Interventions in Cancer Prevention and Cancer Interception ResearchPrevention, diet, interceptionNOT-CA-24-0601/8/2027
Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional)Climate, preventative, social disparities, economic disparitiesR21PAR-23-1521/17/20252/16/2025
Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)Pediatric, birth defects, data analysis, geneticR03PAR-23-0752/16/2025
Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R21 Clinical Trial Not Allowed)Radiopharmaceuticals, radiation therapy, pre-clinicalR21PAR-22-1402/16/2025
Precision Approaches in Radiation Synthetic Combinations (PAIRS, R21 Clinical Trial Optional)Radiation therapy, pre-clinical, clinical trialsR21PAR-22-1991/17/20252/16/2025
(NOSI): Dissemination and Implementation Science for Cancer Prevention and Control in Low Resource EnvironmentsCommunity, prevention, implementationR01, R03, R21NOT-CA-24-0641/8/2028
(NOSI): Advancing Diet and Physical Activity Biomarkers for Assessing Lifestyle Interventions in Cancer Prevention and Cancer Interception Researchbiomarkers, lifestyle interventions, prevention, interception, diet, physical activityR01, R03, R21NOT-CA-24-0741/8/2027
The Confluence of Cancer Stigma and HIV Stigma in HIV-positive Individuals Diagnosed with Cancer (R01 Clinical Trial Optional)HIVR01RFA-CA-25-01111/10/202412/10/2024
The Confluence of Cancer Stigma and HIV Stigma in HIV-positive Individuals Diagnosed with Cancer (R21 Clinical Trial Optional)HIVR21RFA-CA-25-01211/10/202412/10/2024
Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed)Investigator-Initiated Research, surgery, early-stagePAR-25-04410/6/202411/5/2024
Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)Investigator-Initiated Research, surgery, R01PAR-25-04310/7/202411/6/2024
(NOSI): Career Development Opportunities for Research on Cancer in Global Settings at the Center for Global Health at the National Cancer InstituteTraining, Global Health, international, collaboration, (LMICs)K01, K08, K99, R00, R25NOT-CA-24-09811/17/2024
Administrative Supplements to Support Cancer Disparity Collaborative Research (Clinical Trial Optional)health disparities, health equity, collaborativeAdmin SuppPAR-22-11411/19/2024
Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)technology development, innovationR01PAR-22-24211/21/2024
Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)technology development, clinical translation, innovationR01PAR-22-24310/23/202411/22/2024
Cancer Prevention Clinical Trials Network (CP-CTNet): Data Management, Auditing, and Statistical Center (DMASC) (UG1 Clinical Trial Required)prevention, clinical trials, network, data management, biostatisticsUG1RFA-CA-24-02510/24/202411/23/2024
Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed)natural products, interception, chemopreventionUG3, UH3RFA-CA-23-02810/26/202411/25/2024
Impacts of climate change across the cancer control continuum (R01 Clinical Trial Optional)environmental health, exposures, continuum of careR01PAR-23-15310/28/202411/27/2024
National Cancer Institute Program Project Applications for the Years 2023, 2024, and 2025 (P01 Clinical Trial Optional)multi-investigator, collaborative, multidisciplinary, large-scaleP01PAR-23-05912/26/20241/25/2025
(NOSI): Telehealth Research in Cancer Caretelehealth, digital health, remote monitoring, telemedicine, access to care, virtual careR01, R03, R21NOT-CA-24-0333/17/2026
Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)implementation, health services, continuum of care, patient-centered outcomesUG3, UH3PAR-22-2561/15/20252/14/2025
Precision Approaches in Radiation Synthetic Combinations (PAIRS, R01 Clinical Trial Optional)radiation therapy, drug combinations, radiosensitizers, precision medicine, personalized medicineR01PAR-22-1981/6/20252/5/2025
Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R01 Clinical Trial Not Allowed)radionuclides, radiopharmaceuticals, preclinical, theranostics, imaging, therapyR01PAR-22-1392/5/2025
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)molecular, biomarkers, therapies, clinical UH2, UH3PAR-25-0742/14/2025
Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed)Liver, obesity, diabetes, social determinants, epidemiologyR21PA-25-1232/16/2025
Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 Clinical Trial Not Allowed)liver, epidemiology, risk factorsR01PAR-22-0832/5/2025
Co-infection and Cancer (R01 Clinical Trial Not Allowed)infectious diseases, viruses, bacteria, HIV, HPVR01PAR-25-08211/24/2024
Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)biomarkers, assay validation, assay development, translational, diagnosticsR01PAR-24-3042/14/2025
Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)Comprehensive Cancer Control, Immunotherapy, Imaging Technology, Cell BiologyR01PAR-25-0982/5/2025
NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers (UG1 Clinical Trial Not Allowed)clinical trials, translationalUG1RFA-CA-24-0351/24/20252/24/2025
The Metastasis Research Network (MetNet): MetNet Research Projects (U01 Clinical Trial Not Allowed)Systems-level, mechanisms of responses. Therapy, novel, data, collaborativeU01PAR-25-1305/21/20256/20/2025
(NOSI): Administrative Supplements for Assessing Capacity to Address Obesity for Cancer Prevention and Controlobesity, preventionAdmin SuppNOT-CA-25-0042/3/2025
Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)Dissemination, implementation, health disparitiesR21PAR-25-1431/17/20252/16/2025
Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)dissemination, implementation, evidence-based interventions, publicR01PAR-25-1441/6/20252/5/2025
Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)dissemination, implementation, evidence-based interventionsR03PAR-25-2331/17/20252/16/2025
(NOSI): Administrative Supplements to Support Vanguard Study for CSRN InvestigatorsCSRN, administrative supplements, consortiumNOT-CA-24-1111/30/2025
Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)Cancer Control, Population Sciences, Clinical TrialR01PA-25-1722/5/2025
Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)preventative, clinical trials, planning, pilot studiesU34PAR-25-1031/26/20252/25/2025
Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)preventative, clinical trials, planning, feasibility studiesR34PAR-25-1041/26/20252/25/2025
NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)Clinical Trials, Early-stage, diagnosis, precention, disparities, molecules, xenograft, biology, ESIR21PAR-25-1392/13/2025
Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)Exploratory, Early-stage, cancer control, novel, ESIR21PA-25-2531/17/20252/16/2025
Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)Animal models, Translational research, R01PAR-24-3062/5/2025
Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)cancer imaging, inflammation, molecular imaging, PET, MRI, biomarkers, diagnosis, prognosisR01PAR-24-3111/6/20252/5/2025
Academic - Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)Biomedical Imaging, In Vivo Imaging, Cancer Detection, Medical Technology, LimitedPAR-25-0792/5/2025
Co - infection and Cancer (R21 Clinical Trial Not Allowed)Co-infection, epidemiology, mechanistic studiesR21PAR-25-0831/17/20252/16/2025
Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)Nanotechnology, Brain Disorders, Biomedical Systems, BiomarkersR01PAR-25-1065/5/2025
Microbial - based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed)Microbiome, imaging, therapy, immune response, preclinical, bacteria, R01PAR-25-1072/5/2025
Microbial - based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed)Microbiome, imaging, therapy, immune response, preclinical, bacteria, exploratoryR21PAR-25-1082/16/2025
Clinical Characterization of Cancer Therapy - induced Adverse Sequelae and Mechanism - based Interventional Strategies (R01 Clinical Trial Optional)collaborative, therapies, basic, translational, clinical, biomarkers, R01PAR-25-1451/6/20252/5/2025
Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)chemical probes, drug discovery, immunomodulators, high-throughput screening, assay developmentR01PAR-25-1531/6/20252/5/2025
Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)tumor, imagingR01PAR-25-1751/6/20252/5/2025
Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional)alcohol, risk reduction, prevention, public health, behavioral interventions, epidemiologyR01PAR-25-2212/5/2025
Improving Care and Outcomes for Cancer Survivors from Sexual and Gender Minority (SGM) Populations (R01 Clinical Trial Optional)Survivor, treatment, diversity, observationalR01PAR-25-2371/6/20252/5/2025
Biology of Bladder Cancer (R01 Clinical Trial Optional)biology, genetics, novel interventions, R01PAR-25-1291/6/20252/5/2025
Biology of Bladder Cancer (R21 Clinical Trial Optional)Exploratory, biology, genetics, novel interventions, R21PAR-25-1281/17/20252/16/2025
NCI Pathway to Independence Award (K99/R00 – Clinical Trial Not Allowed)postdoctoral, transition, early career, career developmentK99, R00PAR-25-1352/13/2025
Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01 Clinical Trial Optional)health communication, digital health, social media, misinformation, health literacyR01PA-25-2942/5/2025
Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 Clinical Trial Optional)Communication, social media, online tools, health information, publicR21PA-25-2952/16/2025
Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional)biomimetic technologies, bioengineering, regenerative medicineR01PAR-25-1711/6/20252/5/2025
Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)epidemiological studiesU01PAR-25-2481/11/20252/10/2025
Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required)Nanotechnology, Brain Disorders, Biomedical Systems, BiomarkersR01PAR-25-2542/5/2025
Research Opportunities in Established Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed)Established, epidemiology, cancer controlU01PAR-25-2752/28/2025
(NOSI): Dissemination and Implementation Science for Cancer Prevention and Control in Low Resource Environmentsprevention, controlR01, R03, R21NOT-CA-25-0121/8/2028

Can’t find what you’re looking for? Please contact researchdevelopment@cancer.ufl.edu for assistance in finding additional funding opportunities.

NCI Cancer Center badge